Immune checkpoint inhibitors in patients with cancers of unknown primary
- PMID: 37890352
- DOI: 10.1016/j.ejca.2023.113377
Immune checkpoint inhibitors in patients with cancers of unknown primary
Conflict of interest statement
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: ER: Honoraria: Eli Lilly; Travel, Accommodations, Expenses: Pfizer, Roche, Mundipharma; Grants: Gilead (institutional); The remaining authors did not declare any conflict of interest.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
